



Arix Bioscience plc

Result of Annual General Meeting

LONDON, 23 May 2023: Arix Bioscience plc ("Arix" or the "Company") (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces that at its Annual General Meeting (the "Meeting") duly convened and held today, all resolutions as set out on the notice of meeting were duly passed by way of a poll. Resolutions 1 to 11 were passed as ordinary resolutions. Resolutions 12 to 15 were passed as special resolutions.

Full details of the poll results are set out below and will also be available on the Company's [website](#).

| No | RESOLUTION | VOTES FOR | % | VOTES AGAINST | % | TOTAL VOTES | % of ISC VOTED | VOTES WITHHELD |
|----|--|------------|---------|---------------|--------|-------------|----------------|----------------|
| 1 | To receive the Directors' Report and the accounts of the Company for the year ended 31 December 2022 | 68,931,411 | 100.00% | 3,441 | 0.00% | 68,934,852 | 53.28% | 8,440 |
| 2 | To approve the Directors' Remuneration Report | 61,073,950 | 89.25% | 7,358,207 | 10.75% | 68,432,157 | 52.89% | 511,135 |
| 3 | To re-elect Peregrine Moncreiffe as a Director | 68,099,019 | 98.79% | 834,821 | 1.21% | 68,933,840 | 53.28% | 9,452 |
| 4 | To re-elect Maureen O'Connell as a Director | 68,894,053 | 99.94% | 42,077 | 0.06% | 68,936,130 | 53.28% | 7,162 |
| 5 | To re-elect Isaac Kohlberg as a Director | 68,900,656 | 99.98% | 17,184 | 0.02% | 68,917,840 | 53.26% | 25,452 |
| 6 | To re-elect Robert Lyne as a Director | 68,902,689 | 99.95% | 31,595 | 0.05% | 68,934,284 | 53.28% | 9,008 |
| 7 | To elect Dr. Debra Barker as a Director | 68,907,528 | 99.95% | 32,248 | 0.05% | 68,939,776 | 53.28% | 3,516 |
| 8 | To elect Andrew Smith as a Director | 68,921,195 | 99.98% | 13,089 | 0.02% | 68,934,284 | 53.28% | 9,008 |
| 9 | To appoint BDO LLP as auditors of the Company | 68,929,881 | 99.99% | 7,445 | 0.01% | 68,937,326 | 53.28% | 5,966 |
| 10 | To authorise the Audit and Risk Committee of the Company to fix the auditor's remuneration | 68,934,245 | 100.00% | 2,013 | 0.00% | 68,936,258 | 53.28% | 7,034 |
| 11 | To authorise the Directors to allot shares | 65,989,256 | 95.72% | 2,950,520 | 4.28% | 68,939,776 | 53.28% | 3,516 |
| 12 | Authority to disapply statutory pre-emption rights | 62,199,252 | 90.23% | 6,734,680 | 9.77% | 68,933,932 | 53.28% | 9,360 |

| | | | | | | | | |
|----|---|------------|--------|-----------|-------|------------|--------|-------|
| 13 | Additional authority to disapply statutory pre-emption rights | 62,202,105 | 90.23% | 6,731,827 | 9.77% | 68,933,932 | 53.28% | 9,360 |
| 14 | To authorise the Company to purchase its own shares | 68,921,128 | 99.98% | 17,177 | 0.02% | 68,938,305 | 53.28% | 4,987 |
| 15 | Authority to call a general meeting, other than an annual general meeting, on not less than 14 clear days' notice | 68,145,351 | 98.85% | 792,954 | 1.15% | 68,938,305 | 53.28% | 4,987 |

In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>.

The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 25 April 2023, which is available on Arix investor relations [website](#).

[ENDS]

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

About Arix Bioscience plc

Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com